EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER
Abstract. Thirty-seven patients with stage colorectal cancer stage IV were subjected to immunotherapy using a polyantigenic vaccine, prepared, basically, from lyzed cells of murine melanoma (B16) and murine carcinoma (LLC) cells. The inducing course of xenovaccine therapy consisted of 10 subcutaneou...
| Main Authors: | , , , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | Russian |
| 出版: |
St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
2014-07-01
|
| 丛编: | Медицинская иммунология |
| 主题: | |
| 在线阅读: | https://www.mimmun.ru/mimmun/article/view/433 |
| _version_ | 1826534327187406848 |
|---|---|
| author | M. A. Felde D. M. Samarin N. A. Niza A. A. Shishkov O. V. Poveshenko E. A. Kashchenko V. I. Seledtsov G. V. Seledtsova V. A. Kozlov |
| author_facet | M. A. Felde D. M. Samarin N. A. Niza A. A. Shishkov O. V. Poveshenko E. A. Kashchenko V. I. Seledtsov G. V. Seledtsova V. A. Kozlov |
| author_sort | M. A. Felde |
| collection | DOAJ |
| description | Abstract. Thirty-seven patients with stage colorectal cancer stage IV were subjected to immunotherapy using a polyantigenic vaccine, prepared, basically, from lyzed cells of murine melanoma (B16) and murine carcinoma (LLC) cells. The inducing course of xenovaccine therapy consisted of 10 subcutaneous immunizations (5 injections weekly followed by 5 bi-weekly). Consolidating treatment included monthly vaccinations. Ther xenovaccine therapy was not associated with any serious adverse effects, and did not influence the composition of blood lymphocyte subsets. Significant increase in cellular immune reactions to vaccinal carcinoma-associated antigens occurred in the patients after an inducing treatment, as determined by both skin and antigen-driven blastogenesis test. The overall 2-year survival of thirty-seven stage IV colorectal cancer patients was shown to be significantly better, than in control group (37 clinically comparable patients), with median survival rates of 17 and 7 months, respectively. |
| first_indexed | 2024-03-08T05:50:43Z |
| format | Article |
| id | doaj.art-757558f0b1024b68b9dd005a9703770c |
| institution | Directory Open Access Journal |
| issn | 1563-0625 2313-741X |
| language | Russian |
| last_indexed | 2025-03-14T02:21:15Z |
| publishDate | 2014-07-01 |
| publisher | St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists |
| record_format | Article |
| series | Медицинская иммунология |
| spelling | doaj.art-757558f0b1024b68b9dd005a9703770c2025-03-11T17:59:03ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2014-07-0181677210.15789/1563-0625-2006-1-67-72430EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCERM. A. Felde0D. M. Samarin1N. A. Niza2A. A. Shishkov3O. V. Poveshenko4E. A. Kashchenko5V. I. Seledtsov6G. V. Seledtsova7V. A. Kozlov8ГУ НИИКИ СО РАМН, г.НовосибирскГУ НИИКИ СО РАМН, г.НовосибирскГУ НИИКИ СО РАМН, г.НовосибирскГУ НИИКИ СО РАМН, г.НовосибирскГУ НИИКИ СО РАМН, г.НовосибирскГУ НИИКИ СО РАМН, г.НовосибирскГУ НИИКИ СО РАМН, г.НовосибирскГУ НИИКИ СО РАМН, г.НовосибирскГУ НИИКИ СО РАМН, г.НовосибирскAbstract. Thirty-seven patients with stage colorectal cancer stage IV were subjected to immunotherapy using a polyantigenic vaccine, prepared, basically, from lyzed cells of murine melanoma (B16) and murine carcinoma (LLC) cells. The inducing course of xenovaccine therapy consisted of 10 subcutaneous immunizations (5 injections weekly followed by 5 bi-weekly). Consolidating treatment included monthly vaccinations. Ther xenovaccine therapy was not associated with any serious adverse effects, and did not influence the composition of blood lymphocyte subsets. Significant increase in cellular immune reactions to vaccinal carcinoma-associated antigens occurred in the patients after an inducing treatment, as determined by both skin and antigen-driven blastogenesis test. The overall 2-year survival of thirty-seven stage IV colorectal cancer patients was shown to be significantly better, than in control group (37 clinically comparable patients), with median survival rates of 17 and 7 months, respectively.https://www.mimmun.ru/mimmun/article/view/433colorectal cancerxenovaccinecellular immunity |
| spellingShingle | M. A. Felde D. M. Samarin N. A. Niza A. A. Shishkov O. V. Poveshenko E. A. Kashchenko V. I. Seledtsov G. V. Seledtsova V. A. Kozlov EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER Медицинская иммунология colorectal cancer xenovaccine cellular immunity |
| title | EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER |
| title_full | EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER |
| title_fullStr | EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER |
| title_full_unstemmed | EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER |
| title_short | EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER |
| title_sort | evaluation of cellular immune response during xenovaccine therapy of the patients with stage iv of colorectal cancer |
| topic | colorectal cancer xenovaccine cellular immunity |
| url | https://www.mimmun.ru/mimmun/article/view/433 |
| work_keys_str_mv | AT mafelde evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT dmsamarin evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT naniza evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT aashishkov evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT ovpoveshenko evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT eakashchenko evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT viseledtsov evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT gvseledtsova evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer AT vakozlov evaluationofcellularimmuneresponseduringxenovaccinetherapyofthepatientswithstageivofcolorectalcancer |